Don't let the sell-off in the markets scare you off: Now may be an ideal time to buy stocks. Even if you don't have a lot of money that you can afford to invest, there are many great stocks you can buy for less than $100, and over time you can slowly build up your position.
Three growth stocks that look like fantastic buys for the long haul right now are AstraZeneca(NASDAQ: AZN), Uber Technologies(NYSE: UBER), and Arista Networks(NYSE: ANET). Here's why these can be great investments to hang on to for years.
AstraZeneca
Shares of AstraZeneca currently trade at less than $70. This is a stock that can be both a good growth stock and an income-generating investment. Its dividend currently yields 2.3%, which is higher than the S&P 500 average of 1.4%.
But the big reason to invest in AstraZeneca is for its long-term growth potential. The company is investing in growing its pipeline, but it is also using acquisitions to open up new growth opportunities. Last year, it acquired Fusion Pharmaceuticals, a company that develops next-gen cancer treatments involving radiopharmaceuticals, which are more targeted approaches to cancer treatment than chemotherapy.
Through acquisitions and in-house investments, AstraZeneca now has a whopping 191 projects in its pipeline. In addition to oncology, the company has opportunities in rare diseases, respiratory and immunology, cardiovascular, and other therapeutic areas.
AstraZeneca reported more than $54 billion in sales last year, but there's considerably more growth on the horizon. By 2030, it's aiming for $80 billion in sales. This fast-growing stock is a great investment to just buy, put into your portfolio, and forget about.
Uber Technologies
Uber Technologies stock trades at a similar price to AstraZeneca, also below $70. While it doesn't pay a dividend, it also makes for a compelling growth stock. The simplicity and efficiency of its operating model is what makes it an attractive investment.
Investors have been worried that robotaxis will encroach on Uber's turf and eat into its market share, but I'm not convinced they will pose a significant threat to the business. Uber's model relies on its software connecting drivers to customers, rather than on operating a fleet of vehicles, which can be costly and difficult to turn a profit on. That software can work for robotaxis too, so they may prove to be complementary to Uber's growth in the long run. For example, Uber recently partnered with Alphabet's Waymo on the deployment of autonomous vehicles in Austin and Atlanta.
Uber is seeing terrific growth -- sales have more than doubled in three years, going from $17.5 billion in 2021 to just under $44 billion this past year. And over that time, Uber went from being unprofitable to now posting a strong profit margin of 22%. The company may benefit from new opportunities related to robotaxis, as well as by entering more markets to further expand its reach around the globe.
Arista Networks
Another fantastic growth stock to consider buying right now is Arista Networks, which trades at a similar price point to both Uber and AstraZeneca. The tech company provides businesses with networking solutions, helping them upgrade their infrastructure to meet the needs of artificial intelligence (AI) and ensuring they balance their workloads efficiently.
Arista grew its sales by just under 20% last year, to $7 billion; net income also rose by 37% to nearly $2.9 billion. The company can benefit from trends in AI, and while it hasn't generated the sort of returns that chipmaker Nvidia has, there's been a notable correlation in its performance. Over the past three years, while Nvidia's stock has risen more than 300%, Arista has climbed by more than 100%. And as AI stocks have tumbled of late, so too has Arista's valuation.
For investors who are bullish on the opportunities in AI, Arista Networks can make for a compelling buy. With a market cap of around $80 billion and the stock trading at an attractive valuation of 26 times the company's estimated future earnings (based on analyst expectations), it could have a lot of upside in the long run.
Should you invest $1,000 in AstraZeneca Plc right now?
Before you buy stock in AstraZeneca Plc, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AstraZeneca Plc wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $461,558!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $578,035!*
Now, it’s worth notingStock Advisor’s total average return is730% — a market-crushing outperformance compared to147%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor.
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Arista Networks, Nvidia, and Uber Technologies. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy.
